Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 21 , ISSUE 7 ( 2017 ) > List of Articles


Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients

Mohamed Abbas

Keywords : Bemiparin, enoxaparin, Intensive Care Unit, low-molecular-weight heparin, venous thromboembolism

Citation Information : Abbas M. Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients. Indian J Crit Care Med 2017; 21 (7):419-423.

DOI: 10.4103/ijccm.IJCCM_23_17

License: CC BY-ND 3.0

Published Online: 01-07-2018

Copyright Statement:  Copyright © 2017; The Author(s).


Background: Critically ill patients are considered a high-risk group for developing venous thromboembolism (VTE). Due to their impaired cardiopulmonary reserve, these VTEs may result in significant morbidity and mortality. In this study, we compared two types of low molecular weight heparin, enoxaparin, and bemiparin, as regards to their efficacy and safety in VTE prevention among Intensive Care Unit (ICU) patients. Methods: This study was a prospective, randomized trial of 100 critically ill patients who are at high risk for developing VTE were included in this study and assigned to receive subcutaneous injections of either 3500 international units (IU) anti-factor Xa of bemiparin sodium or 40 mg of enoxaparin given once a day and patient were followed for 60 days after initiation of anticoagulant therapy for the development of documented deep venous thrombosis (DVT) using bilateral lower limb venous duplex, documented pulmonary embolism using computed tomography pulmonary angiography, and complications related to injectant anticoagulant. Results: Confirmed DVT was observed in two patients (4%) in the bemiparin group compared with 10 patients (20%) in the enoxaparin group with P < 0.05. Confirmed pulmonary embolism (PE) was observed in seven patients (14%) in the enoxaparin group with no recorded cases of confirmed PE in the bemiparin group (P < 0.05). No deaths were recorded in either group. Adverse events such as ecchymosis or hematoma at the injection site were observed in one patient (2%) in the bemiparin group and eight patients (16%) in the enoxaparin group (P < 0.05). There was no significant statistical difference between both groups as regards other adverse effects and complications related to the injectant anticoagulant. Conclusion: Bemiparin was superior to enoxaparin as a prophylactic anticoagulant for VTE in critically ill patients with less adverse local complications at the injection site. The study was registered on Registration ID: NCT02795065. Registered June 8, 2016.

PDF Share
  1. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-50.
  2. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161(4 Pt 1):1109-14.
  3. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001;161:1268-79.
  4. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977;2:800-1.
  5. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke 2001;32:262-7.
  6. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986;15:84-8.
  7. Crowther MA, Cook DJ, Griffith LE, Devereaux PJ, Rabbat CC, Clarke FJ, et al. Deep venous thrombosis: Clinically silent in the Intensive Care Unit. J Crit Care 2005;20:334-40.
  8. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133 6 Suppl:257S-98S.
  9. Cosmi B, Palareti G. Old and new heparins. Thromb Res 2012;129:388-91.
  10. Alalaf SK, Jawad RK, Muhammad PR, Ali MS, Al Tawil NG. Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: A prospective clinical trial. BMC Pregnancy Childbirth 2015;15:72.
  11. Navarro-Quilis A, Castellet E, Rocha E, Paz-Jiménez J, Planès A; Bemiparin Study Group in Knee Arthroplasty. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial. J Thromb Haemost 2003;1:425-32.
  12. Zierler BK. Ultrasonography and diagnosis of venous thromboembolism. Circulation 2004;109 12 Suppl 1:I9-14.
  13. Desciak MC, Martin DE. Perioperative pulmonary embolism: Diagnosis and anesthetic management. J Clin Anesth 2011;23:153-65.
  14. Wittram C, Maher MM, Yoo AJ, Kalra MK, Shepard JA, McLoud TC. CT angiography of pulmonary embolism: Diagnostic criteria and causes of misdiagnosis. Radiographics 2004;24:1219-38.
  15. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002;30:771-4.
  16. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Crit Care Med 2005;33:1565-71.
  17. Dalen JE. Pulmonary embolism: What have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest 2002;122:1440-56.
  18. Balibrea JL, Altimiras J, Larruzea I, Gómez-Outes A, Martínez-González J, Rocha E; Bemiparin Cooperative Study Group in Surgery for Cancer. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: An audit of practice. Int J Surg 2007;5:114-9.
  19. Ciccone MM, Cortese F, Corbo F, Corrales NE, Al-Momen AK, Silva A, et al. Bemiparin, an effective and safe low molecular weight heparin: A review. Vascul Pharmacol 2014;62:32-7.
  20. Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for Intensive Care patients: Double-blinded, randomised clinical trial. Crit Care 2010;14:R41.
  21. Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Nybo M, Rasmussen B, et al. Acomparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: A double-blinded, randomised controlled trial. Crit Care 2013;17:R75.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.